GHK-Cu

GHK-Cu is a naturally occurring copper-binding tripeptide, and the community runs it mostly for skin rejuvenation and anti-aging, with smaller followings for hair growth and wound healing. People most commonly dose around 2 milligrams daily across a wide reported range, while clinician protocols sit lower, roughly 200 micrograms to 1.5 milligrams daily by injection in four-to-eight-week cycles. Isolated reports of injection-site reactions, flushing, and sleep changes occasionally surface, but none are a consistent theme. The honest caveat: there is no FDA-approved use, and the off-label evidence base is thinner than the discourse suggests, mostly exploratory work without posted results.

Half-life~12 min

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice2.01.73.92.95.0

Measured on 5 of 6 axes

Research Evidence

Evidence shape

GHK-Cu possesses low-tier human evidence, limited to five small-scale treatment studies and a single trial focused on acute punch-biopsy wounds. While the literature covers three distinct indications, the research remains exploratory and lacks the rigor of completed, large-scale clinical trials. The current data landscape is characterized by a reliance on preclinical mechanistic research and a long-tail of single-trial investigations, leaving the peptide without a robust foundation of published, high-quality human outcomes.

Depthhow much
1 registered trial
1 recruiting / active
Breadthhow many areas
3 indications mapped
2 thin / exploratory · 1 animal-only · 1 single-trial long-tail
Qualityhow rigorous
No completed trials
Breadth and depth30 rows captured
Human
direct clinical signal
6
Animal
translational support
12
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

1
USA
1000 mg
$35.00
$0.04/mg
2
--
1000 mg×10
$60.00
$0.06/mg
3
--
1000 mg
$55.00
$0.06/mg
4
US
1000 mg×10
$130.00
$0.13/mg
5
--
100 mg
$13.99
$0.14/mg
6
--
100 mg
$15.99
$0.16/mg

price offers can be sorted by column

1-6 of 394

GHK-CU dosing & protocol

How GHK-CU is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 5
Typical dose
100 mg
typical
0
20 mg
40 mg
60 mg
80 mg
100 mg
across 1 dosed source · darker = more agree
Frequency
daily

Of the five trials in this tier, only one recorded a specific dose — 100 mg subcutaneously, daily; the remaining four reported no dosing details.

5 sources
Clinician practice
Doctor & published-protocol guidance · n = 2
Starting dose
200 µg200 µg – 1.5 mg
start
0
20 mg
40 mg
60 mg
80 mg
100 mg
distribution of 6 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
topical

Clinician protocols dose 200 µg–1.5 mg daily topical (2 sources).

2 sources
Anecdotal
Community-reported real-world use · n = 96
Typical dose
2 mg100 µg – 50 mg
typical
0
20 mg
40 mg
60 mg
80 mg
100 mg
distribution of 117 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mostly daily
Route
subQ
Cycle
varies · e.g. 12 weeks on / 4 weeks off (2 reports)

The typical dose across community reports is 2 mg subQ; among those who state a cadence, most inject daily, while a small number report weekly dosing at around 5 mg.

96 sources